Endometrial Cancer Symposium

2026 Endometrial Cancer Symposium

Abstracts Deadline: April 1, 2026
Event Date: May 1, 2026 (8:00AM – 2:00PM)
Location: Dana-Farber Cancer Institute, Yawkey Building (RM 306-307)

Join us for a symposium on endometrial cancer, sponsored by the federally funded P01 grant entitled, “Targeting Replication Stress and DNA Damage Response in Uterine Cancer”. Speakers include Dr. Casey Cosgrove and David Cortez.

We will review submitted abstracts and select a few compelling abstracts for oral presentation at the symposium. Abstract submission deadline is now April 1, 2026, and should be submitted to Quyen Tran, quyen_tran@dfci.harvard.edu. Selected abstracts will be notified by April 10, 2026.  

TimeDetails | DOWNLOAD THE AGENDA
8:00 – 9:00Registration and Breakfast, Poster Set-up
9:00 – 9:15Welcome and Introduction to Endometrial Cancer, Joyce Liu, MD, MPH
Session 1: Moderated by Ursula Matulonis, MD
9:15 – 10:15Endometrial Cancer Molecular Features and the Mounting Mortality Challenge 
Casey Cosgrove, MD
Associate Professor, Gynecologic Oncology
Ohio State University 
10:15 – 11:00

3 Oral Abstract Presentations (10 mins each; 5 mins Q&A)

Jessica St. Laurent, MD:Actionable Germline Findings in Endometrial Cancer from a Large Multigene Panel Tested Cohort

Elizabeth Stover, MD, PhD: Genomics and clinical features of young-onset endometrial cancer

Xin Cheng, PhD:Divergent cancer-associated fibroblast programs mediate FGFR- and cytokine-driven resistance to PI3Kα inhibition in serous endometrial cancer 

11:00 – 11:30Break
Session 2: Moderated by Panagiotis Konstantinopoulos, MD, PhD
11:30 – 12:30

Replication-coupled DNA damage repair and tolerance mechanisms
David Cortez, PhD
Chair of Biochemistry Department
Hortense B. Ingram Professor of Cancer Research
Professor of Biochemistry
Associate Director for Basic Science Research at Vanderbilt-Ingram Cancer Center Vanderbilt University

12:30 – 1:00

2 Oral Abstract Presentations (10 mins each; 5 mins Q&A)

Elena Ivanova, PhD:DNA fiber–based replication phenotypes distinguish WEE1-inhibitor response in high-grade endometrial cancer patient-derived organoids (PDOs) treated with azenosertib

Zelei Yang, PhD:Defining an RB functional endometrial cancer subtype

1:00 – 2:00Lunch and Poster Viewing

For questions, please email Quyen Tran at quyen_tran@dfci.harvard.edu